Roxwood Medical Conducts Full Launch of MicroCross Catheter in United States

December 14, 2015—Roxwood Medical Inc. announced the commencement of the full launch of the MicroCross catheter for use in the coronary and peripheral vasculatures in the United States. The device, which is offered in two sizes, Micro14 and Micro18, is designed to provide enhanced guidewire support through challenging and tortuous anatomy.

After receiving US Food and Drug Administration approval for the device, the company conducted an initial limited market release in which 500 patients were successfully treated using the MicroCross.

According to the company, the MicroCross is compatible with Roxwood Medical’s CenterCross catheter. MicroCross catheter’s ultra-low profile shaft with variable pitch braid technology and lubricious coating allows for enhanced trackability and guidewire support, while navigating tortuous regions of the coronary and peripheral vasculature.

In Roxwood Medical’s press release, Jeffrey Moses, MD, commented, “I have been impressed with the performance of the catheter in my early experience. The increased complexity of our treatment approach for coronary occlusions puts a lot of demand on the tools we use. The low profile and trackability of Micro14 provides an exciting new tool for us to access and cross these highly complex lesions.” Dr. Moses is Director of the Cardiovascular Interventional Catheterization Laboratory at Columbia University Medical Center in New York, New York.

Fadi A. Saab, MD, added, “Since first using the Micro14 and Micro18, we continue to be struck by the performance of the catheters, which have quickly become an essential part of our critical limb ischemia toolkit. These are now our frontline tools to navigate across difficult lower extremity blockages, leading to effective treatment of our patients’ severe peripheral arterial disease.” Dr. Saab is with the department of cardiovascular medicine at Metro Health Hospital in Wyoming, Michigan.